Upcoming events

EuroPCR 2016: Half of transcatheter heart valves show degeneration within 10 years of TAVI

First study of long-term durability shows high rates of valve degeneration

Paris, France – 17 May 2016: Half of transcatheter heart valves may undergo degeneration within 10 years, according to estimates from the first study investigating the long-term durability of these valves in patients undergoing transcatheter aortic valve implantation (TAVI) reported at EuroPCR 2016.

“TAVI is increasingly being performed in younger patients and in those at lower surgical risk. As a result, life expectancy after transcatheter heart valve implantation will increase. But the durability of these valves has been assessed only over the short- and intermediate term,” explains lead author Danny Dvir, from the Centre for Heart Valve Innovation, St Paul’s Hospital, Vancouver, Canada.

The research group carried out the first long-term evaluation of transcatheter heart valves. They evaluated 704 patients (mean age 82 years) who underwent TAVI more than five years ago between April 2002 and May 2011 in two centres: Vancouver (Canada) and Rouen (France). A total of 378 patients were followed up with repeat echocardiographic examinations for up to 10 years, after excluding patients who died within 30 days of TAVI, those with device failure immediately after TAVI and those having valve-in-valve procedures. Implanted valves included: the Edwards SAPIEN XT (36%), the Edwards SAPIEN (50%) and the Cribier-EdwardsTM valves (14%).

One hundred patients survived at least five years after TAVI and were investigated for valve degeneration, which was defined using central lab adjudicated criteria of moderate/severe intravalvular regurgitation and/or aortic stenosis (mean gradient > 20mmHg) that did not appear within 30 days of the TAVI procedure.

Over this time the study identified 35 cases of valve degeneration. Approximately two-thirds of the failed valves were associated with intravalvular regurgitation and the remained third with valvular stenosis. A few rare cases also showed a mixture of stenosis and regurgitation. Dr Dvir noted that a significant number of valves showed degeneration between five and seven years after TAVI.

Based on their findings the research group reported that the Kaplan-Meier estimate for the eight-year rate of structural valve degeneration was approximately 50%. They noted that

“Physicians performing TAVI in younger patients and in those expected to survive long after the procedure should be aware that the long-term rate of THV degeneration is not negligible, at least for first-generation THV devices,” advises Dr Dvir. He suggests, “Physicians must be mindful of the limitations of the THV they implant and whether patients can be safely treated by another transcatheter approach, such as valve-in-valve, if a THV fails years later.”

For the future, Dr Dvir says, “We hope that the next-generation THV devices than the valves used in this study. Unfortunately we currently have no data to suggest what the durability of new THV devices will be they have been used in clinical cases for less than five years.”

Commenting on the new findings, Pieter Kappetein, from Erasmus Medical Center, Rotterdam, the Netherlands, says, “This is extremely important data and addresses the concerns that many people had when transcatheter heart valve were introduced: will they last as long as surgical bioprostheses? Can we therefore expand the indication to younger patient?” He adds, “Hopefully, the new generation of TAVI will last longer and there might also be a need for self-regenerating tissue-engineered heart valves. He concludes, “Expansion of TAVI indication should only take place in the confines of a randomised trial.”

Contact: Danny Dvir, St Paul’s Hospital, Vancouver, Canada; email: danny.dvir@gmail.com

EuroPCR 2016 session: Tuesday 17 May 11.20-12.20, Late-breaking trials, registries and innovations; Main Arena

Help for journalists to cover EuroPCR 2016

For any press-related inquiries, please contact:
EuroPCR Press Coordinator, Isabelle Uzielli: iuzielli@europcr.com

Register and attend EuroPCR 2016 as a journalist
Press registration for EuroPCR is open to accredited journalists, free of charge. Journalists must hold a valid press card and/or provide a letter of assignment from a recognised publication. To register as press go to http://www.europcr.com/page/press/960-press.html

EuroPCR press releases
EuroPCR press releases can be found at http://www.pcronline.com/

Attend press briefings
For the press briefing schedule check http://www.europcr.com/page/press/960-press.html

EuroPCR abstracts
Abstracts are available online at http://www.pcronline.com/eurointervention/AbstractsEuroPCR2016_issue/abstracts-europcr-2016/

Notes to Editors

What is EuroPCR?
EuroPCR, the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions (EAPCI), a registered branch of the European Society of Cardiology, is the world-leading course in interventional cardiovascular medicine. PCR has established a distinctive format for educational activities in the field of cardiovascular interventions. Beyond its flagship course in Paris that gathers more than 12,000 participants every year, PCR organises annual courses in Singapore, London UK, Dubai EAU, Johannesburg RSA, Istanbul Turkey, Chengdu China and Tokyo Japan.

For further information on EuroPCR, AsiaPCR/SingLIVE, PCR London Valves, GulfPCR-GIM, AfricaPCR, PCR Istanbul Peripheral, PCR-CIT China Chengdu Valves, PCR Tokyo Valves & PCR, please contact: Anne-Sophie Lartigau at aslartigau@europa-organisation.com.

For more information, please visit http://www.pcronline.com/Courses/EuroPCR and follow us on Twitter #EuroPCR

Source: EuroPCR